Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo

被引:81
作者
Fukushima, M [1 ]
Fujioka, A [1 ]
Uchida, J [1 ]
Nakagawa, F [1 ]
Takechi, T [1 ]
机构
[1] Taisho Pharmaceut Co Ltd, Canc Lab 2, Hanno, Saitama 3578527, Japan
关键词
thymidylate synthase; ribonucleotide reductase; dihydropyrimidine dehydrogenase; orotate phosphoribosyltransferase; mRNA; 5-fluorouracil; acquired resistance; 5-fluorouracil metabolism; colorectal carcinoma; human xenograft; S-1;
D O I
10.1016/S0959-8049(01)00174-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A human tumour sub-line resistant to 5-fluorouracil (5-FU) was established by once a day and every 5, with at least 50 administrations of 5-FU to KM12C human colorectal xenografts in nude mice. KM12C tumours treated with 5-FU showed less sensitivity to 5-FU with an inhibition rate (IR) of 7.9%, while non-treated tumours were highly sensitive to 5-FU with an IR of 81.8%. To clarify the mechanism of 5-FU-resistance, the activities of various enzymes and gene expressions involved in the metabolism of 5-FU in both parental and 5-FU-treated KM12C tumours were measured. A 2- to 3-fold increase in thymidylate synthase (TS) activity and 4- to 5-fold decrease in ribonucleotide reductase (RNR) activity were observed in 5-FU-resistant KM12C tumours, while the activities of orotate phosphoribosyltransferase (OPRT) thymidine and uridine phosphorylases (TP,UP) and thymidine kinase (TK) were not markedly changed as a consequence of repeated treatment of KM12C tumours with 5-FU. The expression of TS mRNA was also amplified in accordance with the increased TS activity in a 5-FU-treated tumour sub-line (KM12C/5-FU) compared with that in parental tumours, but changed expressions of both RNR-R1 and RNA-R2 mRNA could not be detected in the 5-FU-resistant tumour sub-line compared with the parental tumours, suggesting possible post-transcriptional regulation of RNR. Moreover, RNR, in addition to TS and OPRT, seemed to be related to the inherent insensitivity to 5-FU in human cancer xenografts. From these results, it may be concluded that RNR activity is one of the acquired or inherent resistant factors, including TS, to 5-FU in human cancer xenografts in vivo. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1681 / 1687
页数:7
相关论文
共 35 条
[21]  
MAEHARA Y, 1982, GANN, V73, P289
[22]  
Okabe H, 1997, ONCOL REP, V4, P685
[23]   Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients [J].
Paradiso, A ;
Simone, G ;
Petroni, S ;
Leone, B ;
Vallejo, C ;
Lacava, J ;
Romero, A ;
Machiavelli, M ;
De Lena, M ;
Allegra, CJ ;
Johnston, PG .
BRITISH JOURNAL OF CANCER, 2000, 82 (03) :560-567
[24]   THYMIDYLATE SYNTHASE INHIBITION AFTER ADMINISTRATION OF FLUOROURACIL WITH OR WITHOUT LEUCOVORIN IN COLON-CANCER PATIENTS - IMPLICATIONS FOR TREATMENT WITH FLUOROURACIL [J].
PETERS, GJ ;
VANDERWILT, CL ;
VANGROENINGEN, CJ ;
SMID, K ;
MEIJER, S ;
PINEDO, HM .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (10) :2035-2042
[25]  
Salonga D, 2000, CLIN CANCER RES, V6, P1322
[26]   5-FLUORO-2'-DEOXYURIDYLATE - COVALENT COMPLEX WITH THYMIDYLATE SYNTHETASE [J].
SANTI, DV ;
MCHENRY, CS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1972, 69 (07) :1855-&
[27]   Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators [J].
Shirasaka, T ;
Shimamato, Y ;
Ohshimo, H ;
Yamaguchi, M ;
Kato, T ;
Yonekura, K ;
Fukushima, M .
ANTI-CANCER DRUGS, 1996, 7 (05) :548-557
[28]  
SHIRASAKA T, 1993, CANCER RES, V53, P4004
[29]  
Shirasaka T, 1996, CANCER RES, V56, P2602
[30]  
SPEARS CP, 1982, CANCER RES, V42, P450